ABL Biotechnologies Peer Comparison

BSE: 526955

₹0.81

₹0.02 (3.05%)

As on 11-Jul-2016IST

Market cap

₹1 Cr

Revenue (TTM)

₹-- Cr

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Edit

	ABL Biotechnologies	Dishman Carbogen	Take Solutions	Lyka Labs	Bharat Immuno
Market cap (₹ Cr)	1	2,758	241	261	69
Revenue (₹ Cr)	--	2,901	85	138	45
Net Profit (₹ Cr)	-0.13	16.16	12.82	-9.39	-16.64
Net Margin (%)	--	0.55	6.38	-6.66	-36.43
RoE (%)	--	0.29	20.84	-9.20	--
Price to Earnings	--	170.66	18.78	--	--
Price-To-Book	0.05	0.42	7.51	2.76	--

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	ABL Biotechnologies	Dishman Carbogen	Take Solutions	Lyka Labs	Bharat Immuno
Operating Revenue	0.04	0.00	703.66	--	46.34
Total Income	0.01	0.22	718.81	--	47.28
Total Expenditure	0.12	0.00	558.57	--	40.77
EBITDA	-0.12	0.00	145.09	--	5.57
Depreciation	0.07	--	26.67	--	1.24
EBIT	-0.18	0.00	118.42	--	4.33
Interest	0.00	0.18	18.28	--	0.41
Other Income	0.01	0.22	15.15	--	0.94
Exceptional Items	--	--	--	--	1.10
Profit before Tax	-0.18	0.03	115.29	--	5.96
Provision for Tax	--	0.01	21.13	--	-6.60
Profit after Tax	-0.18	0.02	94.16	--	12.56

Liabilities (₹ Cr)

	ABL Biotechnologies	Dishman Carbogen	Take Solutions	Lyka Labs	Bharat Immuno
Shareholder's Funds	18.56	0.05	341.95	--	28.35
Minority Interest	0.00	--	37.62	--	--
Non-Current Liabilities	12.79	8.77	143.22	--	-4.70
Current Liabilities	13.89	0.02	217.77	--	50.28
Total Liabilities	45.24	8.83	740.55	--	80.53

Assets (₹ Cr)

	ABL Biotechnologies	Dishman Carbogen	Take Solutions	Lyka Labs	Bharat Immuno
Non-Current Assets	36.10	0.00	346.21	--	9.38
Current Assets	8.81	8.83	394.34	--	64.54
Total Assets	45.24	8.83	740.55	--	80.53
Total Debt*	17.10	8.77	192.73	--	6.86
Net Current Assets	-5.08	8.82	176.57	--	14.26
Contingent Liabilities	--	--	6.38	--	7.80

Cashflow (₹ Cr)

	ABL Biotechnologies	Dishman Carbogen	Take Solutions	Lyka Labs	Bharat Immuno
Cash From Operating Activities	--	-8.96	115.47	--	4.97
Cash Flow from Investing Activities	--	0.22	-81.41	--	-0.04
Cash from Financing Activities	--	8.77	-21.48	--	-2.79
Net Cash Inflow / Outflow	--	0.03	12.58	--	2.14

Ratios

Profitability Ratios

	ABL Biotechnologies	Dishman Carbogen	Take Solutions	Lyka Labs	Bharat Immuno
ROCE (%)	-0.56	4.88	27.40	--	24.91
ROE (%)	-1.24	61.57	31.58	--	56.73
ROA (%)	-0.40	0.50	14.18	--	24.05
EBIT Margin (%)	-1,256.77	--	22.77	--	14.03
Net Margin (%)	-2,757.31	10.19	13.10	--	26.57
Cash Profit Margin (%)	-1,258.51	--	17.17	--	29.74

Growth Ratios

	ABL Biotechnologies	Dishman Carbogen	Take Solutions	Lyka Labs	Bharat Immuno
Revenue Growth (%)	-100.00	--	40.65	--	1,716.12
EBIT Growth (%)	79.18	--	46.52	--	334.30
Net Profit Growth (%)	70.07	0.00	28.02	--	400.61
EPS Growth (%)	70.06	0.00	22.27	--	400.62
Book Value Growth (%)	-0.89	88.96	34.30	--	77.78

Valuation Ratios

	ABL Biotechnologies	Dishman Carbogen	Take Solutions	Lyka Labs	Bharat Immuno
Price / Earnings	0.00	0.00	4.75	--	2.81
Price / Book Value	0.28	0.00	1.19	--	1.25
Dividend Yield (%)	0.00	--	2.95	--	0.00
EV/EBITDA	-191.01	40.74	3.37	--	3.90
Market Cap (₹ Cr)	7.25	--	406.80	--	35.32

Solvency Ratios

	ABL Biotechnologies	Dishman Carbogen	Take Solutions	Lyka Labs	Bharat Immuno
Debt to Equity	1.18	186.25	0.56	--	0.24
Short term debt to equity ratio	0.23	--	0.11	--	0.24
Current Ratio	0.63	456.03	1.81	--	1.28
Quick Ratio	0.63	456.03	1.73	--	0.89
Interest Coverage	-114.14	1.18	7.31	--	15.44

Operating Efficiency Ratios

	ABL Biotechnologies	Dishman Carbogen	Take Solutions	Lyka Labs	Bharat Immuno
Debtors to sales (%)	752.28	--	22.57	--	57.34
Asset Turnover	0.00	0.00	1.06	--	0.89
Receivable days	2,745.81	--	68.12	--	108.73
Inventory Days	0.00	--	7.79	--	83.68
Payable days	0.00	--	78.73	--	100.09
Cash Conversion Cycle	2,745.81	--	-16.50	--	92.32

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.